TDC
RCUS icon

Thompson Davis & Co’s Arcus Biosciences RCUS Stock Holding History

Thompson Davis & Co’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300
Closed -$4K – 775
2018
Q2 		$4K Buy
+300
New +$4.71K 0.01% 541

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thompson Davis & Co's RCUS Position: Q3 2018 in Review

Thompson Davis & Co sold out of Arcus Biosciences (RCUS) in Q3 2018, closing a stake of 300 shares — an estimated $4K sold.

Thompson Davis & Co first reported a position in RCUS in Q2 2018 and held it in 1 quarter. The position peaked at $4K in Q2 2018. 57 funds tracked by Wall St. Rank hold RCUS as of Q3 2018.

  • Thompson Davis & Co reported no remaining Arcus Biosciences position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 300 Arcus Biosciences shares in Q3 2018, an estimated $4K.
  • Thompson Davis & Co first reported a position in Arcus Biosciences in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Arcus Biosciences position peaked at $4K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.